Search Results - aijun+wang

15 Results

Sort By:

Wearable tongue tracker for silent speech interfaces

MagTrack is a lightweight, wearable device that utilizes magnetic fields to track tongue movements, enabling silent speech recognition and other applications like speech therapy. Background Silent speech interfaces (SSIs) aim to restore communication for individuals who have lost their voice but retain the ability to articulate, such as those who...

Published: 10/23/2024 | Inventor(s): Jun Wang, Beiming Cao

Keywords(s):

Category(s): Life sciences > Diagnostic, Life sciences > Imaging

Exosome Mimicking Nanovesicles Making and Biological Use

Exosome-Mimicking Nanovesicles Tech ID: 31786 / UC Case 2019-781-0 Abstract Researchers from the University of California, Davis and California State University, Sacramento have developed a method of synthesizing stem cell-derived, exosome-mimicking, nanovesicles that have the therapeutic potential to rescue apoptotic neurons in culture. Full Description Neurological...

Published: 2/13/2024 | Inventor(s): Harsha Jyothi, Aijun Wang, Lalithasri Ramasubramanian

Keywords(s):

Category(s): Biomedical, Biotechnology

SARS-COV-2 papain-like protease inhibitors as antivirals

Novel compounds and their use as an inhibitor for SARS-CoV-2. Invention Summary: Two oral SARS-CoV-2 antivirals are available, molnupiravir and Paxlovid. However, the limited efficacy, drug-drug interaction, and drug resistance are main challenges facing these two drugs. Additional oral antivirals with novel mechanisms of actions are clearly needed....

Published: 8/20/2024 | Inventor(s): Jun Wang, Edward Arnold, Francesc Ruiz Figueras, Prakash Jadhav, Bin Tan, Ahmadullah Ansari, Ashima Chopra

Keywords(s): Antiviral, Small molecules

Category(s): Technology Classifications > COVID-19, Technology Classifications > Infectious Disease, Technology Classifications > Therapeutics, Technology Classifications > Healthcare & Life Sciences

Novel Main Protease Inhibitors as SARS-CoV-2 Antivirals

This technology encompasses the development of novel inhibitors for the main protease, or Mpro, of SARS-CoV-2. The main protease of SARS-CoV-2 is a validated drug target and could be key to the development of antiviral drugs against the virus. The inhibitors proposed in this technology are notable, as they are potent main protease inhibitors with high...

Published: 2/2/2024 | Inventor(s): Jun Wang

Keywords(s):

Category(s): Technology Classifications > Life Sciences

A Novel Pan-T-Type Calcium Channel Modulator that alleviates Tonic, Neuropathic and Inflammatory Pain

This invention describes a non-opioid method to treat pain using a novel T-type calcium channel blocker. Background: Current treatments for many types of pain typically include opioid painkillers, which pose a significant risk of addiction and overdose in patients, creating a demand for a treatment with less risk and less side-effects. In neuropathic,...

Published: 11/16/2023 | Inventor(s): Rajesh Khanna, Jun Wang

Keywords(s):

Category(s): Technology Classifications, Technology Classifications > Life Sciences > Drug Delivery, Technology Classifications > Life Sciences > Small Molecules

Discovery of Pyrazolopyridine Analogs as Broad-Spectrum Antivirals against Non-Polio Enteroviruses including EV-D68, EVA71, and CVB3

This invention reports the discovery and development of pyrazolopyridine inhibitors that have been shown to be effective in cell culture against multiple strains of non-polio enteroviruses including: EV-D68, EVA71, and CVB3. There are currently no antivirals or vaccines for non-polio enteroviruses, and the health consequences of infection for some...

Published: 1/10/2024 | Inventor(s): Jun Wang, Naoya Kitamura

Keywords(s):

Category(s): Technology Classifications > Life Sciences > Small Molecules, Technology Classifications > Healthcare Portfolios > Infectious Diseases

PLpro Inhibitors Against SARS-CoV-2

There are two cysteine proteases that are encoded by SARS-CoV-2, the main protease (Mpro) and the papain-like protease (PLpro). Both of these proteases have been shown to be essential in viral replication and are validated antiviral drug targets. PLpro cleaves the viral SARS-CoV-2 polyprotein at three sites. In addition, it modulates host immune response...

Published: 7/26/2024 | Inventor(s): Jun Wang, Chunlong Ma, Naoya Kitamura, Yanmei Hu

Keywords(s):

Category(s): Technology Classifications > Healthcare Portfolios > Infectious Diseases, Technology Classifications > Life Sciences > Small Molecules

3D Printing Structural Strength Optimization

Method for optimizing the design of lightweight, high-strength parts with reduced material costs and increased heat dissipation. Background: Additive manufacturing (3D printing) provides increased design and production flexibility. Leveraging that capability, University at Buffalo (UB) researchers have developed an optimization system for designing...

Published: 5/29/2024 | Inventor(s): Rahul Rai, Jun Wang

Keywords(s): Technologies

Category(s): Campus > University at Buffalo, Technology Classifications > Engineering, Technology Classifications > Materials and Chemicals

Discovery of Non-Covalent Inhibitors Targeting the SARS-CoV-2 Main Protease

This technology encompasses the development of novel inhibitors for the main protease, or Mpro, of SARS-CoV-2. The main protease of SARS-CoV-2 is a validated drug target and could be key to the development of more antiviral drugs against the virus. The inhibitors proposed in this technology are notable, as they are non-covalent inhibitors with high...

Published: 11/16/2023 | Inventor(s): Jun Wang, Naoya Kitamura, Chunlong Ma

Keywords(s):

Category(s): Technology Classifications > Life Sciences > Therapeutics, Technology Classifications > Healthcare Portfolios > Infectious Diseases

Discovery of T-Type Calcium Channel Antagonist from Multicomponent Reactions and their Application in Paclitaxel-Induced Peripheral Neuropathy

This invention uses innovative selective T-type antagonists in order to ease pain involved with chemotherapy-induced peripheral neuropathy (CIPN). Background: Chemotherapy remains a frontline treatment for many forms of cancer, however, chemotherapy agents commonly cause severe side effects such as CIPN. While opioids have been used to manage CIPN,...

Published: 11/16/2023 | Inventor(s): Jun Wang, Rajesh Khanna

Keywords(s):

Category(s): Technology Classifications > Healthcare Portfolios > Oncology, Technology Classifications > Life Sciences > Therapeutics

1 2